About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Daily Archives: December 18, 2008
FDA Announces New Recommendations on Evaluating Cardiovascular Risk in Drugs Intended to Treat Type 2 Diabetes
Cardiovascular risk associated with diabetes has been a major issue for those developing medications for diabetics. Yesterday, the FDA issued a press release about new diabetes drug development guidelines that the agency is issuing in relation to the evaluation of … Continue reading
Posted in FDA Policy
Comments Off on FDA Announces New Recommendations on Evaluating Cardiovascular Risk in Drugs Intended to Treat Type 2 Diabetes